Oppenheimer Holdings Inc. (OPY) At $28.65 Forms Top; Icad (ICAD) Shorts Increased By 101.96%

Oppenheimer Holdings Inc. (NYSE:OPY) Logo

Oppenheimer Holdings Inc. (OPY) formed multiple top with $29.80 target or 4.00% above today’s $28.65 share price. Oppenheimer Holdings Inc. (OPY) has $379.35 million valuation. The stock increased 1.96% or $0.55 during the last trading session, reaching $28.65. About 59,950 shares traded or 16.27% up from the average. Oppenheimer Holdings Inc. (NYSE:OPY) has risen 83.28% since June 21, 2017 and is uptrending. It has outperformed by 70.71% the S&P500.

Icad Inc (NASDAQ:ICAD) had an increase of 101.96% in short interest. ICAD’s SI was 61,800 shares in June as released by FINRA. Its up 101.96% from 30,600 shares previously. With 25,500 avg volume, 2 days are for Icad Inc (NASDAQ:ICAD)’s short sellers to cover ICAD’s short positions. The SI to Icad Inc’s float is 0.48%. The stock increased 1.27% or $0.04 during the last trading session, reaching $3.19. About 42,760 shares traded or 45.99% up from the average. iCAD, Inc. (NASDAQ:ICAD) has declined 29.34% since June 21, 2017 and is downtrending. It has underperformed by 41.91% the S&P500. Some Historical ICAD News: ; 22/03/2018 – ICAD 4Q Rev $7.9M; 23/03/2018 – ICAD INC – AMENDMENT EXTENDED MATURITY DATE OF SECOND ADVANCE LOAN FROM AUGUST 7, 2021 TO MARCH 1, 2022; 22/03/2018 ICAD 4Q Loss/Shr 26c; 23/03/2018 – ICAD INC – AMENDMENT INCREASED FINAL PAYMENT FEE FROM 7% TO 8% OF ORIGINAL PRINCIPAL AMOUNT OF LOANS ADVANCED UNDER LOAN AGREEMENT; 19/04/2018 – iCAD Announces Presentation of Positive Clinical Data on Xoft System for Treatment of Early-Stage Breast Cancer and Gynecologic; 14/05/2018 – ICAD 1Q Rev $6.31M; 23/03/2018 – ICAD INC – AMENDMENT EXTENDED DATE TO DRAW SECOND ADVANCE UNDER LOAN AGREEMENT FROM JULY 30, 2018 TO JUNE 30, 2019; 14/05/2018 – ICAD 1Q Loss/Shr 20c; 14/05/2018 – ICAD Expects to Submit PowerLook Tomo Detection Version 2.0 for FDA Approval Shortly; 20/04/2018 – DJ iCAD Inc, Inst Holders, 1Q 2018 (ICAD)

Investors sentiment decreased to 1.12 in Q1 2018. Its down 1.11, from 2.23 in 2017Q4. It dropped, as 7 investors sold Oppenheimer Holdings Inc. shares while 27 reduced holdings. 18 funds opened positions while 20 raised stakes. 5.63 million shares or 5.87% less from 5.98 million shares in 2017Q4 were reported. Ameriprise stated it has 0% of its portfolio in Oppenheimer Holdings Inc. (NYSE:OPY). Bancorp Of America Corp De invested in 0% or 3,235 shares. Chicago Equity Partners Lc owns 86,440 shares. 184,621 are held by Millennium Mgmt Ltd Limited Liability Company. Gsa Partners Limited Liability Partnership holds 0.07% or 50,260 shares. Massachusetts-based Rhumbline Advisers has invested 0% in Oppenheimer Holdings Inc. (NYSE:OPY). Tower Research Cap (Trc) owns 18,600 shares. Burgundy Asset Mgmt invested 0.04% of its portfolio in Oppenheimer Holdings Inc. (NYSE:OPY). Private Capital Mgmt Lc holds 1.15% of its portfolio in Oppenheimer Holdings Inc. (NYSE:OPY) for 283,584 shares. Vanguard holds 0% or 413,967 shares in its portfolio. Balyasny Asset Ltd Liability Corp, a Illinois-based fund reported 8,500 shares. Macquarie Group Limited stated it has 0% in Oppenheimer Holdings Inc. (NYSE:OPY). Ameritas Investment Partners Incorporated stated it has 932 shares or 0% of all its holdings. Wells Fargo And Mn holds 0% of its portfolio in Oppenheimer Holdings Inc. (NYSE:OPY) for 13,956 shares. Duncker Streett And Communication invested in 3,300 shares or 0.02% of the stock.

Among 2 analysts covering Oppenheimer Holdings (NYSE:OPY), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Oppenheimer Holdings had 3 analyst reports since September 14, 2015 according to SRatingsIntel. The firm has “Buy” rating by Sidoti given on Monday, March 21. Macquarie Research upgraded Oppenheimer Holdings Inc. (NYSE:OPY) on Monday, September 14 to “Outperform” rating. The company was maintained on Monday, November 2 by Macquarie Research.

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. The company has market cap of $53.16 million. It operates through two divisions, Cancer Detection and Cancer Therapy. It currently has negative earnings. The firm provides electronic brachytherapy products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy.

Another recent and important iCAD, Inc. (NASDAQ:ICAD) news was published by Nasdaq.com which published an article titled: “iCAD Named 2018 MedTech Breakthrough Award Winner” on June 06, 2018.

Oppenheimer Holdings Inc. (NYSE:OPY) Institutional Positions Chart